

GRM3和DTNBP1基因單一核?酸多態性與台灣精神分裂症之關聯性 = Correlations of single nucleotide polymorphisms in GRM3 and DT

黃清德、蔡明勳

E-mail: 354804@mail.dyu.edu.tw

摘要

精神分裂症 (schizophrenia) 是一種最嚴重的精神疾病，近期的研究顯示約64~81%的精神分裂症病患與基因遺傳有關。近年的研究指出穀胺酸神經傳導路徑與精神分裂症有關，因此我們挑選GRM3和DTNBP1基因來分析基因多態性與精神分裂症的關聯。GRM3產物是在神經突觸的穀胺酸G蛋白受體，對於穀胺酸的神經傳遞扮演重要的角色；DTNBP1是負責編碼dysbindin蛋白在人腦的多個區域表現，該蛋白參與建立和維持神經元和肌肉細胞的連繫，以正確完成大腦的指令，是穀胺酸和多巴胺神經傳導路徑的關鍵蛋白之一。本研究針對藥物控制效果良好(第一型)和藥物控制效果不佳(第二型)的精神分裂症病患與正常人的GRM3和DTNBP1這兩基因的六組單一核?酸多態性 (single nucleotide polymorphisms, SNPs) : rs2299225、rs1468412、rs7758659、rs760666、rs875462與rs3213207，分別設計引子來進行聚合?鏈鎖反應，擴增SNP附近序列。首先確認是否有插入或缺失突變，之後再進行序列分析，確認個別SNP是否有點突變和附近序列的正確性，並比較這些突變是否有統計意義，以了解DTNBP1和GRM3的個別SNP與精神分裂症是否有關聯。精神分裂症發病年齡統計結果顯示，第一型與第二型精神分裂症病患在發病年齡上無顯著差異；在性別與發病年齡上，第一型與第二型精神分裂症病患皆無顯著差異。此外我們還發現41~50歲的病患人數百分比第一型精神分裂症小於第二型精神分裂症。由對偶基因頻率的關聯分析結果得知，GRM3基因的rs1468412和DTNBP1基因的rs3213207與精神分裂症有關聯性 ($p=0.004$ 和 $p=0.043$)，而其餘四組SNPs皆與精神分裂症無關聯性。在精神分裂症與性別在對偶基因頻率的關聯性分析結果發現，rs1468412達顯著水準 ($p=0.01$)。在DTNBP1基因的rs875462鄰近位置NT_007592.15:g.15478430(A)發現與精神分裂症具有關聯性 ($p=0.009$)。本研究結果證明GRM3和DTNBP1的基因多態性與台灣精神分裂症病患有關聯性，rs1468412和rs3213207這兩組SNPs變異，可能在我們台灣人族群是造成罹患精神分裂症的因子。

關鍵詞：精神分裂症、GRM3基因、DTNBP1基因、單一核?酸多態性

目錄

目錄	封面內頁	簽名頁	中文摘要	iii	英文摘要	v	誌謝	vii	目錄	viii	圖目錄	xi	表目錄	xii	1. 緒論	1	1.1 研究背景	1	1.2 研究動機	2	1.3 研究目的	3	2. 文獻回顧	4	2.1 精神分裂症介紹	4	2.2 精神分裂症分類	4	2.3 精神分裂症治療	5	2.4 精神分裂症可能致病因素	6	2.5 基因突變與精神分裂症之關聯性	7	2.6 多巴胺傳導路徑之功能以及受器介紹	11	2.7 穀胺酸傳導路徑之功能及其受器介紹	12	2.8 GRM3和DTNBP1基因與精神分裂症之關聯	14	2.9 如何選定GRM3與DTNBP1基因之SNPs進行精神分裂症關聯性分析	16	3. 材料與方法	17	3.1 實驗材料與設備	17	3.2 實驗流程	18	3.3 樣本來源	19	3.4 採血與血球分離並萃取純化染色體DNA	21	3.5 以分光光度計分析DNA濃度再以膠體電泳分析DNA品質	22	3.6 聚合?鏈鎖反應擴增特定的DNA片段	23	3.7 目標DNA片段大小確認與序列分析	24	3.8 統計分析	25	4. 結果與討論	26	4.1 精神分裂症病患與正常人發病年齡統計	26	4.2 精神分裂症病患之發病年齡比較分析	27	4.3 GRM3基因之對偶基因頻率統計結果	29	4.3.1 GRM3基因之SNP-rs1468412的統計結果	29	4.3.2 GRM3基因之SNP-rs2299225的統計結果	34	4.4 DTNBP1基因之對偶基因頻率統計結果	39	4.4.1 DTNBP1基因之SNP-rs7758659的統計結果	39	4.4.2 DTNBP1基因之SNP-rs760666的統計結果	40	4.4.3 DTNBP1基因之SNP-rs875462的統計結果	42	4.4.4 DTNBP1基因之SNP-rs3213207的統計結果	43	4.5 SNPs實驗結果與NCBI提供序列比較	48	4.6 SNPs鄰近位置可能和精神分裂症相關的突變	49	4.7 討論	54	5. 結論	59	參考文獻	60	附錄	68	圖目錄	圖1. 三種穀胺酸受器種類及其訊息傳遞	14	圖2. 實驗流程圖	18	圖3. GRM3基因之rs1468412的膠體電泳圖	30	圖4. GRM3基因之rs1468412的序列統計結果	30	圖5. GRM3基因之rs1468412的序列之男、女分別比例結果	32	圖6. GRM3基因之rs2299225的膠體電泳圖	35	圖7. GRM3基因之rs2299225的序列統計結果	35	圖8. GRM3基因之rs2299225的序列之男、女分別比例結果	37	圖9. DTNBP1基因之rs7758659的膠體電泳圖	39	圖10. DTNBP1基因之rs7758659的序列統計結果	40	圖11. DTNBP1基因之rs760666的膠體電泳圖	41	圖12. DTNBP1基因之rs760666的序列統計結果	41	圖13. DTNBP1基因之rs875462的膠體電泳圖	42	圖14. DTNBP1基因之rs875462的序列統計結果	43	圖15. DTNBP1基因之rs3213207的膠體電泳圖	44	圖16. DTNBP1基因之rs3213207的序列統計結果	45	圖17. DTNBP1基因之rs3213207的序列之男、女分別比例結果	46	圖18. DTNBP1基因之g.15478430的序列統計結果	50	圖19. DTNBP1基因之g.15478685的序列統計結果	51	圖20. DTNBP1基因之g.15478430的序列之男、女分別比例結果	52	表目錄	表1. 樣本類型和性別、平均年齡統計表	20	表2. 有抽取到DNA的樣本類型和性別統計	21	表3. 精神分裂症病患發病年齡分層表	27	表4. 第一型與第二型精神分裂症病患發病年齡比較	28	表5. 第一型與第二型精神分裂症男性與女性病患發病年齡比較	28	表6. 精神分裂症與rs1468412的關聯性分析	31	表7. 精神分裂症與rs1468412的對偶基因頻率在性別上的關聯性	
----	------	-----	------	-----	------	---	----	-----	----	------	-----	----	-----	-----	-------	---	----------	---	----------	---	----------	---	---------	---	-------------	---	-------------	---	-------------	---	-----------------	---	--------------------	---	----------------------	----	----------------------	----	----------------------------	----	--	----	----------	----	-------------	----	----------	----	----------	----	------------------------	----	--------------------------------	----	-----------------------	----	----------------------	----	----------	----	----------	----	-----------------------	----	----------------------	----	-----------------------	----	---------------------------------	----	---------------------------------	----	-------------------------	----	-----------------------------------	----	----------------------------------	----	----------------------------------	----	-----------------------------------	----	-------------------------	----	---------------------------	----	--------	----	-------	----	------	----	----	----	-----	---------------------	----	-----------	----	----------------------------	----	-----------------------------	----	-----------------------------------	----	----------------------------	----	-----------------------------	----	-----------------------------------	----	------------------------------	----	--------------------------------	----	------------------------------	----	-------------------------------	----	------------------------------	----	-------------------------------	----	-------------------------------	----	--------------------------------	----	--------------------------------------	----	---------------------------------	----	---------------------------------	----	---------------------------------------	----	-----	---------------------	----	-----------------------	----	--------------------	----	--------------------------	----	-------------------------------	----	---------------------------	----	------------------------------------	--

分析 33 表8. 精神分裂症與rs2299225的關聯性分析 36 表9. 精神分裂症與rs2299225的對偶基因頻率在性別上的關聯性分析 38 表10. 精神分裂症與rs3213207的關聯性分析 45 表11. 精神分裂症與rs3213207的對偶基因頻率在性別上的關聯性分析 47 表12. SNPs序列實驗結果與NCBI資料庫比較表 48 表13. 精神分裂症與g.15478430的關聯性分析 50 表14. 精神分裂症與g.15478685的關聯性分析 51 表15. 精神分裂症與g.15478430的對偶基因頻率在性別上的關聯性分析 53

參考文獻

- 1.孔繁鐘。1997。DSM-IV 精神疾病的診斷與統計。合計圖書出版社。台北，台灣。
- 2.吳銘斌，林秀娟，黃國峰。2001。遺傳與人類疾病。台灣醫學5(5):569-576。
- 3.李懿璋。2008。精神分裂症病患與正常人之DNA甲基化網絡的差異。國立中央大學生物資訊與系統生物研究所碩士論文。
- 4.周葦，萬紅嬌，楊翠萍。2010。精神分裂症相關基因的研究進展。實用臨床醫學11(4):128-130。
- 5.洪采璋。2005。訊息傳遞路徑DARPP-32/PP-1在精神分裂症患者之分子遺傳研究。慈濟大學人類遺傳研究所碩士論文。
- 6.孫偉，?俊，王力芳，曲梅，阮燕燕，盧天蘭，岳偉華，張岱。2009。精神分裂症斷裂基因1(DISIC1)多態性與精神分裂症的關聯研究。中國心理衛生雜誌23(8):590-594。
- 7.徐巧玲。2008。NMDAR2A和NEFL作為精神分裂症之易感性基因研究。慈濟大學人類遺傳研究所碩士論文。
- 8.徐霽君。2009。以蛋白質交互作用的觀念解釋精神分裂症NRG1-CACNG2基因交互作用的機制。國立陽明大學生命科學院生物醫學資訊研究所碩士論文。
- 9.張翔，盧楠，顏懷城，謝馨，肖嵐。2011。精神分裂症斷裂基因1在精神分裂症發病機制中的研究進展。中國藥業20(3):77-78。
- 10.陸雪芬。2008。精神分裂症病患與家庭成員面臨疾病遺傳不確定情境之生活經驗探討。國立陽明大學臨床護理研究所碩士論文。
- 11.湯華盛編著。2007。精神疾病與自殺防治。第2-4頁。行政院衛生署自殺防治中心出版。台北，台灣。
- 12.白雅美醫師(民88年11月7日)。精神分裂病(3)【心靈園地】取自 <http://www.psychpark.org/paper1/article/?keyword=%A5%D5%B6%AE%AC%FC>
- 13.維基百科，自由的百科全書(民100年12月27日)。精神分裂症【維基百科】取自 <http://zh.wikipedia.org/wiki/%E7%B2%BE%E7%A5%9E%E5%88%86%E8%A3%82%E7%97%87>
- 14.NCBI資料庫。 <http://www.ncbi.nlm.nih.gov/snp>
- 15.Austin, J. 2005. Schizophrenia: an update and review. *Journal of Genetic Counseling*. 14(5): 329-340.
- 16.Albalushi, T., Horiuchi, Y., Ishiguro, H., Koga, M., Inada, T., Iwata, N., Ozaki, N., Ujike, H., Watanabe, Y., Someya, T. and Arinami, T. 2008. Replication Study and Meta-Analysis of the Genetic Association of GRM3 Gene Polymorphisms With Schizophrenia in a Large Japanese Case-Control Population. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 147B(3): 392-396.
- 17.Andreoua, D., Saetre, P., Kahler, A. K., Wergee, T., Andreassen, O. A., Agartz, I., Sedvall, G. C., Hall, H., Terenius, L. and Jonsson, E. G. 2011. Dystrobrevin-binding protein 1 gene (DTNBP1) variants associated with cerebrospinal fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in healthy volunteers. *European Neuropsychopharmacology*. 21(9): 700-704.
- 18.Bedard, P., Boucher, R., Daigle, M.M., Di Paolo, T., 1984. Similar effect of estradiol and haloperidol on experimental tardivedyskinesia in monkeys. *Psychoneuroendocrinology*. 9(4): 375 – 379.
- 19.Baune, B. T., Suslow, T., Be ' ste, C., Birosova, E., Domschke, K., Sehlmeier, C. and Konrad, C. 2010. Association between genetic variants of the metabotropic glutamate receptor 3 (GRM3) and cognitive set shifting in healthy individuals. *Genes, Brain and Behavior*. 9(5): 459 – 466.
- 20.Bassett, A. S., Chow, E. W., Waterworth, D. M. and Brzustowicz, L. 2001. Genetic Insights into Schizophrenia. *Canadian Journal of Psychiatry*. 46(2): 131-7.
- 21.Bassett, A. S., Marshall, C. R. and Lionel, A. C. 2008. Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. *Human Molecular Genetics*. 17(24): 4045-4053.
- 22.Benson, M. A., Newey, S. E., Martin-Rendon, E., Hawkes, R. and Blake, D. J. 2001. Dysbindin a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. *Biological Chemistry*. 276: 24232-24241.
- 23.Bishop, J. R., Miller, D. D., Ellingrod, V. L. and Holman, T. 2011. Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia. *Human Psychopharmacology: Clinical and Experimental*. 26(1): 28 – 34.
- 24.Chen, Q., He, G., Chen, Q., Wu, S., Xu, Y., Feng, G., Li, Y., Wang, L. and He, L. 2005. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. *Schizophrenia Research*. 73(1): 21 – 26.
- 25.Chien, Y. L., Liu, C. M., Fann, C. S. J., Liu, Y. L. and Hwu, H. G. 2009. Association of the 3 Region of COMT with Schizophrenia in Taiwan. *Journal of the Formosan Medical Association*. 108(4): 301-309.
- 26.Cherylyn, S. Y. T., Woon, P. S., Liu, J. J., Ong, W. Y., Tsai, G. C. and Sim, K. 2010. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: A decade of advance. *Neuroscience and Biobehavioral Reviews*. 34(6): 958 – 977.
- 27.Dumontheil, I., Roggeman, C., Ziermans, T., Peyrard-Janvid, M., Matsson, H., Kere, J. and Klingberg, T. 2011. Influence of the COMT Genotype on Working Memory and Brain Activity Changes During Development. *Biological Psychiatry*. 70(3): 222-229.
- 28.Duan, J., Martinez, M., Sanders, A. R., Hou, C., Burrell, G. J., Krasner, A. J., Schwartz, D. B. and Gejman, P. V. 2007. DTNBP1 (Dystrobrevin Binding Protein 1) and Schizophrenia: Association Evidence in the 3' End of the Gene. *Human Heredity*. 64(2): 97-106.
- 29.Domschke, K., Lawford, B., Young, R., Voisey, J., Morris, C. P., Roehrs, T., Hohoff, C., Birosova, E., Arolt, V. and Baune, B. T. 2011. Dysbindin (DTNBP1) - A role in psychotic depression? *Journal of Psychiatric Research*. 45(5): 588-595.
- 30.Fujii, Y., Shibata, H., Kikuta, R., Makino, C., Tani, A., Hirata, N., Shibata, A., Ninomiya, H., Tashiro, N. and Fukumaki, Y. 2003. Positive association of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. *Psychiatric Genetics*. 13(2): 71-76.
- 31.Giegling, I., Genius, J., Benninghoff, J. and Rujescu, D. 2010. Genetic findings in schizophrenia patients related to alterations in the intracellular Ca-homeostasis. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 34(8): 1375 – 1380.
- 32.Hwu, H. G., Hong, C. J., Lee, Y. L., Lee, P. C. and Lee, S. F. C. 1998. Dopamine D4 Receptor Gene Polymorphisms and Neuroleptic Response in Schizophrenia. *Biological Psychiatry*. 44(6): 483-487.
- 33.Haukvik, U. K., Saetre, P., McNeil, T., Bjerkan, P. S., Andreassen, O. A., Werge, T., Jonsson, E. G. and Agartz, I. 2010. An exploratory model for G x E interaction on hippocampal volume in schizophrenia; obstetric

complications and hypoxia-related genes. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 34(7): 1259 – 1265.

34. Jablensky, A., Morar, B., Wiltshire, S., Carter, K., Dragovic, M., Badcock, J. C., Chandler, D., Peters, K. and Kalaydjieva, L. 2011. Polymorphisms associated with normal memory variation also affect memory impairment in schizophrenia. *Genes, Brain and Behavior*. 10(4): 410-417.

35. Kirov, G., O'Donovan, M. C. and Qwen, M. J. 2005. Finding schizophrenia genes. *Journal of Clinical Investigation*. 115(6): 1440-1448.

36. Karayiorgou, M. and Gogos, J. A. 2006. Schizophrenia genetics: uncovering positional candidate genes. *European Journal of Human Genetics*. 14: 512-519.

37. Kulkarni, J., De Castella, A. R., Headey, B., Marston, N., Sinclair, K., Lee, S., Gurvich, C., Fitzgerald, P. B., Burger, B. 2011. Estrogens and men with schizophrenia: Is there a case for adjunctive therapy? *Schizophrenia Research*. 125(2-3): 278 – 283.

38. Lang, U. E., Puls, I., Muller, D. J., Strutz-Seebohm, N. and Gallinat, J. 2007. Molecular mechanisms of Schizophrenia. *Cellular Physiology and Biochemistry*. 20(6): 687-702.

39. Liao, S. Y., Lin, S. H., Liu, C. M., Hsieh, M. H., Hwang, T. J., Liu, S. K., Guo, S. C., Hwu, H. G. and Chen, W. J. 2009. Genetic variants in COMT and neurocognitive impairment in families of patients with schizophrenia. *Genes, Brain and Behavior*. 8(2): 228-237.

40. Liu, C. M., Liu, Y. L., Fann, C. S. J., Yang, W. C., Wu, J. Y., Hung, S. I., Chen, W. J., Chueh, C. M., Liu, W. M., Liu, C. C., Hsieh, M. H., Hwang, T. J., Faraone, S. V., Tsuang, M. T. and Hwu, H. G. 2007. No association evidence between schizophrenia and dystrobrevin-binding protein 1 (DTNBP1) in Taiwanese families. *Schizophrenia Research*. 93(1-3): 391-398.

41. Liu, Y. L., Fann, C. S. J., Liu, C. M., Chang, C. C., Yang, W. C., Hung, S. I., Yu, S. L., Hwang, T. J., Hsieh, M. H., Liu, C. C., Tsuang, M. M., Wu, J. Y., Jou, Y. S., Faraone, S. V., Tsuang, M. T., Chen, W. J. and Hwu, H. G. 2007. More evidence supports the association of PPP3CC with Schizophrenia. *Molecular Psychiatry*. 12: 966-974.

42. Liu, C. M., Liu, Y. L., Fann, C. S. J., Chen, W. J., Yang, W. C., Ouyang, W. C., Chen, C. Y., Jou, Y. S., Hsieh, M. H., Liu, S. K., Hwang, T. J., Faraone, S. V., Tsuang, M. T. and Hwu, H. G. 2006. Association evidence of schizophrenia with distal genomic region of NOTCH4 in Taiwanese families. *Genes, Brain and Behavior*. 6(6): 497-502.

43. Mueser, K. T. and McGurk, S. R. 2004. Schizophrenia. *The Lancet*. 363(9426): 2063-2072.

44. Mossner, R., Schuhmacher, A., Schulze-Rauschenbach, S., Kuhn, K. U., Rujescu, D., Rietschel, M., Zobel, A., Franke, P., Wolwer, W., Gaebel, W., Hafner, H., Wagner, M. and Maier, W. 2008. Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia. *European Neuropsychopharmacology*. 18(10): 768 – 772.

45. Norton, N., Williams, H. J., Dwyer, S., Ivanov, D., Preece, A. C., Gerrish, A., Williams, N. M., Yerassimou, P., Zammit, S., O'Donovan, M. C. and Owen, M. J. 2005. No evidence for association between polymorphisms in GRM3 and schizophrenia. *BMC Psychiatry*. 5: 23.

46. Pae, C. U., Mandelli, L., Ronchi, D. D., Kim, J. J., Jun, T. Y., Patkar, A. A. and Serretti, A. 2009. Dysbindin gene (DTNBP1) and schizophrenia in Korean population. *European Archives of Psychiatry and Clinical Neuroscience*. 259(3): 137-142.

47. Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., Mosolov, S. N., Neznanov, N. G., Reznik, A. M., Smulevich, A. B., Tochilov, V. A., Johnson, B. G., Monn, J. A. and Schoepp, D. D. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. *Nature Medicine*. 13: 1102-1107.

48. Park, H. J., Levitt, J., Shenton, M. E., Salisbury, D. F., Kubicki, M., Kikinis, R., Jolesz, F. A. and McCarley, R. W. 2004. An MRI study of spatial probability brain map differences between first-episode schizophrenia and normal controls. *NeuroImage*. 22(3): 1231-1246.

49. Petronis, A., Paterson, A. D. and Kennedy, J. L. 1999. Schizophrenia: An Epigenetic Puzzle? *Schizophrenia Bulletin*. 25(4): 639 – 655.

50. Rapoport, J. L., Addington, A. M., Frangou, S. and Psych, M. R. 2005. The neurodevelopmental model of schizophrenia: update 2005. *Molecular Psychiatry*. 10: 434-449.

51. Sumner, B. E., Fink, G., 1998. Testosterone as well as estrogen increases serotonin 2A receptor mRNA and binding site densities in the male rat brain. *Molecular Brain Research*. 59(2): 205-214.

52. Saiz, P. A., Garcia-Portilla, M. P., Arango, C., Morales, B., Arias, B., Corcoran, P., Fernandez, J. M., Alvarez, V., Coto, E., Bascaran, M. T., Bousono, M., Fananas, L. and Bobes, J. 2010. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 34(1): 26 – 31.

53. Seeman, P. and Kapur, S. 2000. Schizophrenia: more dopamine, more D2 receptors. *Proceedings of the National Academy of Sciences*. 97(14): 7673-7675.

54. Schoepp, D. D. 1994. Novel functions for subtypes of metabotropic glutamate receptors. *Neurochemistry International*. 24(5): 439-449.

55. Thimm, M., Krug, A., Kellermann, T., Markov, V., Krach, S., Jansen, A., Zerres, K., Eggermann, T., Stocker, T., Shah, N. J., Nothen, M. M., Rietschel, M. and Kircher, T. 2010. The effects of a DTNBP1 gene variant on attention networks: an fMRI study. *Behavioral and Brain Functions*. 6: 54.

56. Voisey, J., Swagell, C. D., Hughes, I. P., Lawford, B. R., Young, R. M. and Morris, C. P. 2010. Analysis of HapMap tag-SNPs in dysbindin (DTNBP1) reveals evidence of consistent association with schizophrenia. *European Psychiatry*. 25(6): 314 – 319.

57. Voisey, J., Swagell, C. D., Hughes, I. P., Connor, J. P., Lawford, B. R., Young, R. M. and Morris, C. P. 2010. A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia. *Behavioral and Brain Functions*. 6(1): 41.

58. Voglis, G. and Tavernarakis, N. 2006. The role of synaptic ion channels in synaptic plasticity. *EMBO Reports*. 13(7): 1104-1110.

59. Weickert, C. S., Straub, R. E., McClintock, B. W., Hashimoto, R. and Hyde, T. M. 2004. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. *Archives of General Psychiatry*. 61(6): 544-555.

60. Zhang, J. P., Burdick, K. E., Lencz, T. and Malhotra, A. K. 2010. Meta-Analysis of Genetic Variation in DTNBP1 and General Cognitive Ability. *Biological Psychiatry*. 68(12): 1126 – 1133.